论文部分内容阅读
目的探讨14-3-3ζ在T1期非小细胞肺癌(NSCLC)中的表达及其临床病理意义。方法采用免疫组化、免疫印迹及RT-PCR技术检测110例T1期NSCLC及癌旁正常肺组织中14-3-3ζ蛋白的表达。结果 T1期NSCLC中14-3-3ζ蛋白及mRNA表达水平均较正常肺组织明显增强,14-3-3ζ的表达与患者的年龄、性别及病理学分型不相关。但随着肺癌分化程度的降低,14-3-3ζ的表达逐渐增强。在淋巴结转移阳性的癌组织中,14-3-3ζ表达高于淋巴结转移阴性的癌组织。生存曲线分析结果显示14-3-3ζ表达阴性患者的5年生存率及平均生存时间均高于表达阳性者。结论 14-3-3ζ与肺癌的分化程度、淋巴结转移及患者预后密切相关,提示14-3-3ζ有可能作为判断T1期NSCLC发展与预后的生物学指标之一。
Objective To investigate the expression of 14-3-3ζ in T1-stage non-small cell lung cancer (NSCLC) and its clinicopathological significance. Methods Immunohistochemistry, Western blot and RT-PCR were used to detect the expression of 14-3-3ζ protein in 110 cases of T1-stage NSCLC and adjacent normal lung tissues. Results The expression level of 14-3-3ζ protein and mRNA in stage T1 NSCLC was significantly higher than that in normal lung tissue. The expression of 14-3-3ζ was not correlated with the age, sex and pathological type of the patient. However, as the degree of differentiation of lung cancer decreased, the expression of 14-3-3ζ gradually increased. In the positive lymph node metastasis, the expression of 14-3-3ζwas higher than that in the negative lymph node metastasis. Survival curve analysis showed that patients with negative 14-3-3ζ expression had higher 5-year survival rate and longer mean survival time than those with positive expression. Conclusion 14-3-3ζ is closely related to the degree of differentiation, lymph node metastasis and prognosis of patients with lung cancer, suggesting that 14-3-3ζ may be used as one of the biological indicators to judge the development and prognosis of T1-stage NSCLC.